NCT05240274 (POWERED) is a Phase 2 clinical trial of Metformin in Post-transplant Diabetes Mellitus, sponsored by Barts & The London NHS Trust.

Who is sponsoring NCT05240274?

NCT05240274 is sponsored by Barts & The London NHS Trust.

What drugs are being tested in NCT05240274?

Interventions in NCT05240274: Metformin, Placebo.

What condition does NCT05240274 study?

NCT05240274 studies Post-transplant Diabetes Mellitus, New Onset Diabetes After Transplant, New Onset Diabetes After Transplantation, Kidney Transplant; Complications, Renal Transplantation, End Stage Renal Disease, Metformin.

Is NCT05240274 still recruiting?

NCT05240274 is currently completed. Last updated 18 October 2022.

Last reviewed 2022-10-18 · How we verify

NCT05240274: POWERED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The POWERED Study: Prophylaxis With Metformin to Prevent PTDM

Completed Phase 2 Last updated 18 October 2022

What this trial tests

Phase 2 trial testing Metformin in Post-transplant Diabetes Mellitus in 60 participants. Completed in 30 August 2022.

Timeline

25 January 2019

Primary endpoint
30 May 2022

30 August 2022

Quick facts

Lead sponsor	Barts & The London NHS Trust
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	60
Start date	25 January 2019
Primary completion	30 May 2022
Estimated completion	30 August 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Placebo

Conditions studied

Post-transplant Diabetes Mellitus — all drugs for Post-transplant Diabetes Mellitus →
New Onset Diabetes After Transplant — all drugs for New Onset Diabetes After Transplant →
New Onset Diabetes After Transplantation — all drugs for New Onset Diabetes After Transplantation →
Kidney Transplant; Complications — all drugs for Kidney Transplant; Complications →

Sponsor

Barts & The London NHS Trust — full company profile →

Who can join

Adults 18 to 75, any sex, with Post-transplant Diabetes Mellitus or New Onset Diabetes After Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PrOphylaxis With mEtformin to pREvent PTDM: a single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients undergoing renal transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current practices in prevention, screening, and treatment of diabetes in kidney transplant recipients: European survey highlights from the ERA DESCARTES Working Group.
Laghrib Y, Hilbrands L, Oniscu GC, Crespo M, et al · · 2025 · cited 4× · PMID 39839808 · DOI 10.1093/ckj/sfae367

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other Barts & The London NHS Trust trials

Trials by the same sponsor.

NCT05753085 — Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment · NA · withdrawn
NCT07047235 — Substrate Remodelling and Targeted Ablation in AF · NA · recruiting
NCT06871215 — Inflammation and Infective Endocarditis · withdrawn
NCT07076524 — MuScle WastIng and DysphaGia iN CriticAlly IlL Patients (SIGNAL) · recruiting
NCT06596486 — A Comparison of CoolStick With Ethyl Chloride for the Assessment of Light Touch · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05240274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barts & The London NHS Trust
Last refreshed: 18 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05240274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing